Is PazOP aNIb the Preferred fIrst-LINe treatmeNt fOr metastatIc reNaL ceLL carcINOma?
Bibliographic record
Abstract
CoMMEntARy: Highlights of the 8 Annual Meeting of the Canadian Association of Genitourinary Medical Oncologists included a debate between Dr. Kylea Potvin from the London Health Sciences Centre and Dr. Piotr Czaykowski of CancerCare Manitoba in Winnipeg on the optimal treatment for metastatic renal cell carcinoma. Sunitinib is an oral small molecule multikinase inhibitor considered the de facto standard of care in first-line treatment for patients with metastatic clear cell renal cell cancer. Pazopanib is another multikinase inhibitor active in renal cell cancer. Although both agents are believed to exert their clinical effects through inhibition of vascular endothelial growth factor receptors (VEGFR), pazopanib has been proposed as an equally efficacious but less-toxic alternative to sunitinib. At the time of the debate, results of a first-line open-label randomized trial comparing sunitinib with pazopanib using a noninferiority design had been presented at the 2012 European Society of Medical Oncology (ESMO) Annual Meeting. More recently, the results of the trial have been formally published. The debaters provided a spirited and entertaining debate that identified the most important issues when reviewing these results and considering their application in clinical practice. The motion proposed for debate was: “Pazopanib is the preferred first-line treatment for metastatic renal cell carcinoma.” Dr. Czaykowski argued the affirmative and Dr. Potvin the negative.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.011 | 0.069 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.003 | 0.002 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.003 | 0.005 |
| Scholarly communication | 0.003 | 0.007 |
| Open science | 0.005 | 0.001 |
| Research integrity | 0.043 | 0.050 |
| Insufficient payload (model declined to judge) | 0.008 | 0.006 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".